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INTRODUCTION 
Famotidine is a histamine H2-receptor antagonist that 
inhibits stomach acid production, and it is commonly used 
in the treatment of peptic ulcer disease (PUD) and 
gastroesophageal reflux disease (GERD/GORD). It is 
commonly marketed by Johnson & Johnson/Merck under 
the trade names Pepcidine and Pepcid and by Astellas 
under the trade name Gaster. Unlike cimetidine, the first 
H2 antagonist, famotidine has no effect on the cytochrome 
P450 enzyme system, and does not appear to interact with 
other drugs.
1
 
Oral drug administration has been the predominant route 
for drug delivery. During the past two decades, numerous 
oral delivery systems have been developed to act as drug 
reservoirs from which the active substance can be released 
over a defined period of time at a predetermined and 
controlled rate. The reasons for this are essentially 
physiological and usually affected by the GI transit of the 
form, especially its gastric residence time (GRT), which 
appears to be one of the major causes of the overall transit 
time variability.
2
 
Gastroretentive floating microspheres are low-density 
systems that have sufficient buoyancy to float over gastric 
contents and remain in stomach for prolonged periods. As 
the system floats over gastric contents, the drug is released 
slowly at a desired rate resulting in increased gastric 
retention with reduced fluctuations in the plasma drug 
concentration. When microspheres come in contact with 
gastric fluid, the gel formers, polysaccharides, and 
polymers hydrate to form a colloidal gel barrier that 
controls the rate of fluid penetration into the device and 
consequent drug release. As the exterior surface of the 
dosage form dissolves, the gel layer is maintained by the 
hydration of the adjacent hydrocolloid layer. The air 
trapped by the swollen polymer lowers the density and 
confers buoyancy to the microspheres. However, a 
minimal gastric content is needed to allow proper 
achievement of buoyancy
3-8
. 
PREFORMULATION STUDIES 
Preformulation testing is an investigation of physical and 
chemical properties of drug substance alone and when 
combined with excipients. It is the first step in the rational 
development of dosage form. 
ANALYSIS OF FAMOTIDINE 
Indentification of drug by IR Spectra 
The IR spectrum of famotidine in KBr dispersion was 
analysed using ABB Bomen model MB 104 Fourier 
Transform Infrared Spectrophotometer. From the IR 
spectrum obtained interpretations were made and 
compared with that of standard. 
 
ABSTRACT 
The main aim of this study is to develop a gastro retentive multiple unit floating drug delivery system for a drug which is 
poorly absorbed from lower gastrointestinal tract of famotidine. The hollow micro spheres were prepared by the emulsion 
solvent diffusion technique using eudragit RS 100 as a release rate controlling polymer in the ratios 1:1, 1:2 ,1:3,and 1:4.The 
prepared microspheres were evaluated for drug-polymer compatibility, micromeritic properties, drug entrapment efficiency, in-
vitro buoyancy and drug release studies. The mean particle size increased with increase in the polymer concentration. The 
micromeritic properties were found to be improved when compared to pure drug .Scanning electron microscopy confirmed the 
hollow structure with smooth external surface. The drug and polymer were found to be compatible as seen in IR studies. The 
entrapment efficiency of formulation E1-E4 were 70.42%, 70.12%, 69.22% and 67.78% and for the formulation C1-C4 were 
72.19%, 68.67%, 67.14% and 66.87%, cellulose acetate containing microspheres showed a desirable high drug content and 
entrapment efficiency respectively. The microspheres floated up to 10 h over the surface of the gastric buffer medium and the 
buoyancy percentage was found to be in the range of 60-39% of E1-E4and C1-C4. In-vitro drug release studies showed that 
the prepared microspheres exhibited prolonged drug release for more than 12 hours. The mechanism of drug release wasfound 
to be a combination of both peppas and zero order release kinetics. The developed floating microspheres of aceclofenac may 
be used for prolonged drug release for at least 12 h for maximizing the therapeutic efficacy along with patient compliance. 
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Figure 1: IR Spectra of Famotidine 
Standard calibration of famotidine in 0.1N HCl 
Procedure 
In a 100 ml standard flask, stock solution was prepared by 
dissolving 100 mg of famotidine in 5 ml methanol and 
made up to the volume with 0.1N HCl. From this stock 
solution (1%w/v), serial dilutions were made by 
withdrawing 5 ml, 10 ml, 15 ml, 20 ml and 25 ml and 
transferred individually into 10 ml standard flask and the 
volume was made up to the mark using 0.1N  HCl. The 
absorbance of resulting solutions was measured using 
shimadzu UV-1601 spectrophotometer at 265 nm and the 
values are given in fig 2. 
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Figure 2: Standard calibration of famotidine in 0.1N HCl 
MATERIALS AND METHOD: 
FORMULATION DEVELOPMENT 
Preparation of famotidine floating hollow microspheres 
using Eudragit RL 100 
Microspheres were prepared by emulsion solvent diffusion 
method
9
. Four different ratios (E1-E4) of floating hollow 
microspheres of famotidine were prepared by using 
Eudragit RL 100 as polymer calculated quantity (as 
mentioned in table 4) of Eudragit RL 100 and Glyceryl 
monostearate were dissolved in 20 ml of mixture of 
ethanol and dichloromethane (1:1) to get a homogenous 
polymer solution. Famotidine was dispersed uniformly in 
the polymer solution and then it was poured slowly in to 
200 ml of 0.75% w/v polyvinyl alcohol in distilled water. 
The emulsion formed was stirred continuously for 2 hours 
using propeller type agitator at 1500 rpm. The temperature 
was maintained at 40
o
C. The finely dispersed droplets of 
the polymer solution of drug were solidified in the aqueous 
phase via diffusion of the solvent, leaving the cavity of 
microspheres filled with water. Hollow microspheres 
formed were filtered using nylon cloth and washed 
repeatedly with distilled water. 
 
Table 1: (formulation of famotidine floating hollow microspheres E1-E4) 
Sl.No. Ingredients 
Quantity 
E1 
(1:1) 
E2 
(1:2) 
E3 
(1:3) 
E4 
(1:4) 
1 Famotidine 500 mg 250 mg 250 mg 250 mg 
2 Eudragit RL 100 500 mg 500 mg 750 mg 1000 mg 
3 Glyceryl monostearate 250 mg 250 mg 375 mg 500 mg 
4 Ethanol : Dichloromethane (1:1) 20 ml 20 ml 20 ml 20 ml 
5 Polyvinyl Alcohol (0.75% w/v) 200 ml 200 ml 200 ml 200 ml 
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Preparation of famotidine floating hollow microspehers 
using cellulose acetate 
Four different ratio of (C1 (1:1), C2 (1:2), C3 (1:3), C4 
(1:4) ) famotidine floating hollow microspheres were 
prepared using cellulose acetate were prepared by same 
procedure as that of Eudragit RL 100. The solvent system 
used was acetone: ethyl acetate in the ratio of 1:1. 
Calculated quantities for four different ratios are 
mentioned in table 2 
 
Table 2: formulation of famotidine floating hollow microspheres C1-C4 
S.No. Ingredients 
Quantity 
C1 
(1:1) 
C2 
(1:2) 
C3 
(1:3) 
C4 
(1:4) 
1 Famotidine 500 mg 250 mg 250 mg 250 mg 
2 Cellulose acetate 500 mg 500 mg 750 mg 1000 mg 
3 Glyceryl monostearate 250 mg 250 mg 375 mg 500 mg 
4 Acetone : ethyl acetate (1:1) 20 ml 20 ml 20 ml 20 ml 
5 Polyvinyl Alcohol (0.75% w/v) 200 ml 200 ml 200 ml 200 ml 
 
CHARACTERIZATION OF MICROSPHERES 
Particle size 
The size distribution in terms of d(avg) of microspheres of 
formulations (E1-E4) and (C1-C4) using optical 
microscopic method with the help of a calibrated ocular 
micrometer
57
 . The results are shown in fig 3. 
Entrapment efficiency 
To determine the entrapment efficiency 50 mg of 
microspheres was taken in a 50 ml standard flask, 10 ml of 
methanol was added to solubilize and made up to the 
volume with distilled water. The drug content was 
determined by measuring the absorbance at 265 nm using 
Shimadzu UV 1601 spectrophotometer.  
The percentage drug entrapment efficiency of 
microspheres were calculated by using the formula  
Amount of drug actually present 
% entrapment efficiency =  -----------------------------  x 100 
Theoretical drug load expected 
The results are shown in table 4 
Buoyancy percentage 
Floating behavior of hollow microspheres was studied in a 
USP XXIV dissolution apparatus (Type II) by spreading 
the microspheres (300 mg) on a 0.1mol L 
-1
 HCl 
containing 0.02% between 80 as a surfactant. The medium 
was agitated with a paddle rotating at 100 rpm and 
maintained at 37°C. After 12 hrs, both the floating and the 
settled portions of microspheres were collected separately. 
The microspheres were dried and weighed. Buoyancy 
percentage was calculated using the formula. 
                                                    
                 Weight of buoyant microspheres 
% buoyancy of microspheres =   -------------------------------------------------    x   100 
              Initial weight of buoyant microspheres 
 
The results are shown in Table 5. 
In vitro drug release study  
The release rate of famotidine from microspheres was 
determined using USP dissolution testing apparatus I 
(Basket type). The dissolution test was performed using 
900 ml of 0.1N HCl, at 37 ± 0.5°C at100 rpm
10
. 
Withdrawn samples (5 ml) were analyzed 
spectrophotometrically at 265 nm. The volume was 
replenished with the same amount of fresh dissolution 
fluid each time to maintain the sink condition. All 
experiments were performed in triplicate. Linear 
regression was used to analyze the in vitro release 
mechanism. 
Mechanism of drug release  
 
 
The in vitro data was treated according to Zero order, First 
order, Higuchi, Korsmeyer Peppas and Hixson-Crowell 
equation and the coefficient of correlation was determined. 
Zero order Equation - % released = K.time 
First order Equation – log (fraction unreleased) = K/2.303 
x time 
Higuchi Equation - % released = K. time 
0.5
 
Korsmeyer Peppas Equation - %released = K.time 
n
 
Hixson Crowell Equation– (fraction of unreleased) 1/3 = 1-
K.time 
The results are given in Table-7 and in fig 4 
Refabrication and evaluation of selected famotidine 
floating hollow microspheres 
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Microspheres of selected formulations E1-A and C1-A 
were prepared based on the prototype formulation (E1 and 
C1) to assess the reproducibility. The method of 
preparations of E1-A and C1-A were same as that of E1 
and C1 respectively.  
Table 3: Refabrication of selected formulations E1-A and C1-A 
SL. No. Ingredients 
Quantity 
E1-A C1-A 
1 Famotidine 500 mg 500 mg 
2 Cellulose Acetate - 500 mg 
3 Eudragit RL 100 500 mg - 
4 Glyceryl monostearate 250 mg 250 mg 
5 Ethanol : Dichloromethane (1:1) 20 ml - 
6 Ethyl Acetate : Acetone (1:1) - 20 ml 
7 Polyvinyl Alcohol (0.75%) 200 ml 200 ml 
 
Characterization of the Selected Formulations (E1-A 
and C1-A) 
Characteristics of microspheres such as particle size, drug 
content, entrapment efficiency, percentage buoyancy and 
in vitro release were evaluated. 
MORPHOLOGY: Size and Shape 
The external and internal morphology of the microspheres 
were studied by scanning electron microscopy (SEM). The 
samples for SEM were prepared by lightly sprinkling on a 
double adhesive tape stuck to an aluminum stub. The stubs 
were then coated with platinum to a thickness of about 10 
Å under an argon atmosphere using a gold sputter module 
in a high-vacuum evaporator. Afterwards, the stubs 
containing the coated samples were placed in the scanning 
electron microscope (JSM-6360A, JEOL, Tokyo, Japan) 
chamber. The samples were then randomly scanned and 
photomicrographs were taken at the acceleration voltage of 
15 kV to investigate the internal morphology, hollow 
microspheres were cut with a knife. The SEM 
photomicrographs of formulations E1-A and C1-A are 
shown in fig 3.  
 
        
(a)      (b) 
           
(c)      (d) 
Figure 3: Scanning electron microphotographs of floating hollow microspheres of famotidine: (a) & (b) surface and cross-
sectional morphology of C1-A respectively (c) & (d) surface and cross-sectional morphology of the formulation E1-A 
respectively. 
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RESULTS:  
Characterization of particle size: 
0
50
100
150
200
250
E1 E2 E3 E4 C1 C2 C3 C4
Formulation code
s
iz
e
 (
μ
m
)
 
Figure 4: Particle size distribution of formulations E1-E4 and C1-C4 
 
Table 4: Drug entrapment efficiency in formulations (E1-E4 and C1-C4) 
Sl.No
. 
Formulation code 
Entrapment efficiency (%) 
Mean ± SD 
1 2 3 
1 E1 71.05 70.28 69.95 70.42 ± 0.56 
2 E2 71.2 69.18 69.98 70.12 ± 1.01 
3 E3 69.24 70.18 68.25 69.22 ± 0.96 
4 E4 69.03 67.04 67.29 67.78 ± 1.08    
5 C1 72.25 71.11 73.21 72.19  ± 1.05 
6 C2 68.98 69.01 68.64 68.87 ± 0.20 
7 C3 67.19 66.91 67.34 67.14 ± 0.21 
8 C4 67.56 66.14 66.92 66.87 ± 0.71 
 
 
Table 5: Buoyancy percentage of formulations E1-E4 and C1-C4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sl.No. Formulation code 
Buoyancy (%) after 12 h 
Mean ± SD 
1 2 3 
1 E1 70.17 69.11 68.36 69.21 ± 0.09 
2 E2 67.15 68.05 66.52 67.24 ± 0.76 
3 E3 66.16 67.29 65.95 66.46 ± 0.72 
4 E4 64.29 64.64 63.99 64.30 ± 0.32 
5 C1 71.11 70.75 71.84 71.23 ± 0.55 
6 C2 65.34 64.61 66.1 65.35 ± 0.74 
7 C3 59.26 59.97 61.21 60.14 ± 0.98 
8 C4 58.86 59.12 60.37 59.45 ± 0.80 
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Table 6: In vitro release data 
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Figure 5: Comparison of in vitro drug release profile of formulations E1-E4 and C1-C4 
 
Table 7: In-vitro kinetics data for formulations E1-E4 and C1-C4 
 
In vitro release data of famotidine from the formulationE1,E2,E3,E4&C1,C2, C3,C4 
 
E1 E2 E3 E4 C1 C2 C3 C4 
24.32 ± 0.57 18.57 ± 0.46 14.46 ± 0.22 12.87 ± 0.85 19.74 ± 0.25 15.66 ± 0.18 13.26 ± 0.48 10.39 ± 0.32 
26.48 ± 0.05 21.69 ± 0.29 18.28 ± 0.65 13.80 ± 0.14 22.66 ± 0.27 19.27 ± 0.38 15.88 ± 0.24 12.33 ±0 .48 
28.51 ± 0.23 26.23 ± 0.17 20.43 ± 0.61 16.89 ± 0.26 28.00 ± 0.23 22.32 ± 0.83 18.79 ± 0.69 15.33 ± 0.71 
31.53 ± 0.65 29.95 ± 0.62 24.57 ± 0.57 18.99 ± 0.12 33.23 ± 0.37 26.69 ± 0.14 22.15 ± 0.10 17.93 ± 0.68 
34.49 ± 0.18 32.01 ± 0.54 28.10 ± 0.16 20.52 ± 0.82 37.73 ± 0.85 30.29 ± 0.67 26.08 ± 0.85 20.06 ± 0.15 
37.68 ± 0.54 34.92 ± 0.23 30.58 ± 0.68 23.72 ± 0.17 41.92 ± 0.44 34.85 ± 0.64 29.62 ± 0.32 22.19 ±0. 74 
41.45 ± 0.71 37.70 ± 0.11 34.63 ± 0.74 27.57 ± 0.66 45.30 ± 0.90 37.77 ± 0.44 34.02 ± 0.48 26.51 ± 0.49 
44.18 ± 0.11 41.70 ± 0.98 36.80 ± 0.50 29.51 ± 0.71 49.53 ± 0.45 41.93 ± 0.62 37.17 ± 0.74 30.56 ± 0.73 
47.84 ± 0.47 45.36 ± 0.41 40.25 ± 0.40 32.32 ± 0.52 53.78 ± 0.21 44.96 ± 0.93 40.70 ± 0.87 33.94 ± 0.73 
51.10 ± 0.22 49.39 ± 0.12 43.08 ± 0.52 34.36 ± 0.55 57.64 ± 0.23 50.03 ± 0.18 43.25 ± 0.29 35.87 ± 0.78 
62.53 ± 0.96 50.57 ± 0.83 45.86 ± 0.26 36.41 ± 0.32 63.30 ± 0.19 52.60 ± 0.34 47.37 ± 0.26 39.42 ± 0.51 
 
Formulation Code 
Coefficient of correlation (r
2
) 
0 order 1
st
 order Higuchi 
Korsmeyer Peppas Hixson 
crowell r 
2 
value
 ‘n’ value 
E1 0.8585 0.9903 0.990 0.865 0.285 0.891 
E2 0.8848 0.9407 0.974 0.966 0.337 0.9253 
E3 0.9175 0.9579 0.986 0.968 0.384 0.9466 
E4 0.9184 0.9486 0.974 0.932 0.365 0.9398 
C1 0.9238 0.991 0.995 0.865 0.285 0.9612 
C2 0.9359 0.9718 0.984 0.963 0.408 0.9631 
C3 0.9503 0.9764 0.982 0.956 0.434 0.97 
C4 0.9585 0.9733 0.969 0.963 0.408 0.9698 
Lakshmanamurthy et al                      Journal of Drug Delivery & Therapeutics; 2013, 3(6), 207-214                        213 
© 2011, JDDT. All Rights Reserved                                                       ISSN: 2250-1177                                                      CODEN (USA): JDDTAO 
Table 8: Characterization of selected formulations E1-A and C1-A 
aMean ± SD, n = 3 
S.No. Parameter 
Observation
a
 
E1-A C1-A 
1 Mean Particle Size (μm) 171.5 ± 1.818 165.2 ± 2.164 
2 Entrapment Efficiency (%) 70.1 ± 0.45 72.05 ± 0.95 
3 Buoyancy (%) 69.05 ± 0.15 70.95 ± 0.35 
         
Table 9: In vitro release data of famotidine from the 
formulation E1-A 
a
Cumulative % 
Drug release 
a
Cumulative % Drug 
release 
E1-A C1-A 
24.60 ± 0.65 19.05 ± 0.39 
27.11 ± 0.52 21.56 ± 0.11 
29.15 ± 0.11 27.30 ± 0.63 
32.17 ± 0.21 32.46 ± 0.53 
35.06 ± 0.36 36.27 ± 0.99 
38.33 ± 0.58 41.34 ± 0.96 
41.60 ± 0.85 44.93 ± 0.71 
44.97 ± 0.39 48.88 ± 0.62 
48.84 ± 0.48 52.99 ± 0.32 
51.89 ± 0.87 57.60 ± 0.17 
62.15 ±0. 43 63.05 ± 0.76 
 
In vitro drug release profile of formulations E1-A and 
C1-A 
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Figure 6: In vitro drug release profile of formulations 
E1-A and C1-A
 
Table 10: In vitro kinetics data for refabricated formulations E1-A and C1-A 
 
 
 
 
 
 
RESULTS & DISCUSSION  
The results indicated that the mean particle size or average 
diameter d avg) of microspheres was in the range of 153.6-
201.9. Cellulose acetate polymer containing microspheres 
were smaller in size than that of Eudragit RL 100 coated 
microspheres. 
The results shown in table 5 indicate the percentage of 
entrapment efficiency of formulations E1-E4 and C1-C4. 
The drug content of all formulations was determined 
spectrophotometrically. The entrapment efficiency of 
formulation E1-E4 were 70.42%, 70.12%, 69.22% and 
67.78% and for the formulation C1-C4 were 72.19%, 
68.67%, 67.14% and 66.87%. The results shows cellulose 
acetate containing microspheres showed a desirable high 
drug content and entrapment efficiency. 
The results shown in table 6 indicate the percentage 
buoyancy formulations E1-E4 and C1-C4. The percentage 
buoyancy of formulations E1-E4 at the end of 12 h were 
found to be 69.21%, 67.24%, 66.46% and 64.3% and for 
the formulations C1-C4 at he end of 12 h were 71.23%, 
65.35%, 60.14% and 59.45%. The results indicates that 
increase in concentration of polymers, Eudragit  RL 100 
and cellulose acetate decreases the floating time. 
Formulation C1 of cellulose acetate coated microspheres 
and E1 of Eudragit RL 100 coated microspheres were 
found to be best. 
The results shown in table 7 indicate the in vitro drug 
release data of formulations E1-E4 and C1-C4. The 
cumulative percentage drug release of E1-E4 at the end of 
10 h were 62.53%, 50.64%, 45.86% and 36.41% it 
indicates that increase in concentration of Eudragit RL 100 
decreases the release rate of drug. The cumulative drug 
release of C1-C4 at the end of 10 h was 63.30%, 52.60%, 
47.37% and 39.42%. Increase in concentration of cellulose 
acetate tends to control the release of famotidine from the 
formulations. 
The data obtained for in vitro release were fitted in to 
equations for the zero order, first order and Higuchi release 
models. The interpretation of data was based on the value 
of the resulting regression coefficient. The in vitro drug 
 
Formulation Code 
 
Coefficient of correlation (r
2
) 
0 order 1
st
 order Higuchi 
Korsmeyer Peppas Hixson 
crowell r 
2 
value
 ‘n’ value 
E1-A 0.856 0.989 0.990 0.875 0.282 0.895 
C1-A 0.935 0.988 0.991 0.980 0.422 0.968 
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release showed the highest regression coefficient values 
for Higuchi’s model, indicating diffusion to be the 
predominant mechanism of drug release. The formulation 
E1 and C1 using Eudragit RL 100 and cellulose acetate 
respectively showed constant rate of release and hence 
these two formulations were chosen as best and 
refabricated table no 8. 
The results shown in table 9, indicate the d(avg) of 
microspheres of formulations E1-A and C1-A were found 
to be 171.5 μm and 165.2 μm respectively. The percentage 
entrapped and buoyancy percentage after 12 h were found 
to be 70.1% (E1-A), 72.05% (C1-A) and 69.05% (E1-A), 
70.95% (C1-A) respectively. The percentage cumulative 
drug release of E1-A and C1-A at the end of 10 h were 
found to be 62.15% and 63.05% respectively. The data’s 
obtained were compared respectively with that of E1 and 
C1. The results were almost similar and hence showed 
good reproducibility. 
CONCLUSION 
The formulation using Eudragit RL 100 and cellulose 
acetate showed a constant rate of release. Thus, prepared 
floating hollow microspheres of famotidine may prove to 
be potential candidates for a multiple-unit drug delivery 
device adaptable for any intragastric condition. 
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